Profile data is unavailable for this security.
About the company
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
- Revenue in INR (TTM)45.60bn
- Net income in INR15.57bn
- Incorporated1981
- Employees4.20k
- LocationNatco Pharma LtdNatco House, Road No 2, Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 023547532
- Fax+91 4 023545298
- Websitehttps://www.natcopharma.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India Ltd | 8.78bn | 2.40bn | 101.94bn | 583.00 | 42.46 | 26.55 | 40.49 | 11.61 | 104.25 | 104.25 | 381.40 | 166.73 | 1.80 | 4.48 | 40.57 | -- | 49.09 | -- | 66.76 | -- | 73.80 | -- | 27.33 | -- | 3.37 | 148.65 | 0.0607 | -- | 21.24 | -- | 32.65 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.22bn | 2.20k | 20.67 | -- | 18.25 | 4.47 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 115.99bn | 1.21k | 52.26 | -- | 33.78 | 5.65 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.63bn | 1.57k | 40.42 | -- | 33.00 | 10.84 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 127.16bn | 990.00 | 20.78 | -- | 18.35 | 6.09 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 134.67bn | 978.00 | 31.23 | -- | 15.88 | 1.70 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 138.63bn | 16.57k | 22.00 | -- | 14.99 | 1.91 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 142.33bn | 4.07k | 25.55 | -- | 17.29 | 2.80 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 168.02bn | 1.80k | 93.80 | -- | 63.97 | 10.67 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 171.27bn | 4.20k | 11.00 | -- | 9.52 | 3.76 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 188.45bn | 3.56k | 43.03 | -- | 24.86 | 6.12 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 202.22bn | 7.13k | -- | -- | 29.22 | 2.28 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 211.00bn | 3.40k | 64.40 | -- | 42.89 | 9.72 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Wockhardt Ltd | 31.51bn | 220.00m | 212.86bn | 2.30k | 990.09 | -- | 90.58 | 6.76 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 220.03bn | 802.00 | 109.49 | -- | 91.09 | 10.10 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Pfizer Ltd | 24.82bn | 8.54bn | 224.69bn | 1.60k | 26.32 | -- | 24.61 | 9.05 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
Data as of Mar 04 2026. Currency figures normalised to Natco Pharma Ltd's reporting currency: Indian Rupee INR
10.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Belgrave Capital Management Ltd.as of 31 Dec 2025 | 4.15m | 2.31% |
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2025 | 4.09m | 2.29% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 3.53m | 1.97% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.92m | 1.07% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.48m | 0.83% |
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 1.41m | 0.79% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 981.07k | 0.55% |
| Jupiter Asset Management Ltd.as of 31 Oct 2025 | 912.75k | 0.51% |
| Sundaram Asset Management Co. Ltd.as of 31 Jan 2026 | 643.39k | 0.36% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 407.51k | 0.23% |
More ▼
Data from 30 Jun 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
